



BLA 761303/Original 1

**COMPLETE RESPONSE**

Regeneron Pharmaceuticals, Inc.  
Attention: Hsiao-Chi Lo, PhD  
Director, Regulatory Affairs  
777 Old Saw Mill River Road  
Tarrytown, NY 10591-6707

Dear Dr. Lo:

Please refer to your biologics license application (BLA) (b) (4)

(b) (4)

(odronextamab).

We have administratively designated your application as follows:

(b) (4)

The subject of this Complete Response letter is for **BLA 761303/Original 1**.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

**CLINICAL**

- (1) The Agency has determined that a confirmatory trial is required to be underway for odronextamab for follicular lymphoma prior to approval.<sup>1</sup> However, a confirmatory trial in follicular lymphoma with odronextamab is not considered to be underway. (b) (4), you had enrolled (b) (4) patients in the safety run-in portion of OLYMPIA-1, (b) (4) patients in the dose-finding portion of OLYMPIA-2, and (b) (4) patients in the dose-finding portion of OLYMPIA-5, and (b) (4)

<sup>1</sup> Federal Food, Drug, and Cosmetic Act (FD&C Act) sections 506(c)(2)(A)(i) and (D)

patients have been enrolled in the confirmatory portions of these trials. The current conduct and projected completion date of any of these OLYMPIA trials in follicular lymphoma do not provide sufficient assurance of timely completion of the trial(s).

To support resubmission of the BLA, you must address this deficiency. After enrollment and analysis of Part 1 (safety run-in or dose-finding) is completed for your intended confirmatory trial(s) in follicular lymphoma, we recommend you request a meeting with the Agency to discuss trial benchmarks (e.g., enrollment goals, site activation, proportion of primary endpoint events accrued, trial completion date) to allow measurement of the progress of the trial(s). You should demonstrate in your submission that your milestones are appropriate and that, prior to approval, you will demonstrate sufficient progress in the conduct of the confirmatory portion of the confirmatory trial(s) to provide sufficient assurance of timely completion of the trial(s).

### **PRESCRIBING INFORMATION**

We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources<sup>2</sup> and Pregnancy and Lactation Labeling Final Rule<sup>3</sup> websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) – a checklist of important format items from labeling regulations and guidances.

If you revise labeling, use the SRPI checklist to ensure that the Prescribing Information conforms with format items in regulations and guidances. Your response must include updated content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format as described at FDA.gov.<sup>4</sup>

### **CARTON AND CONTAINER LABELING**

We reserve comment on the proposed labeling until the application is otherwise adequate.

### **MEDICATION GUIDE**

We reserve comment on the proposed Medication Guide until the application is otherwise adequate.

### **PROPRIETARY NAME**

---

<sup>2</sup> <https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources>

<sup>3</sup> <https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule>

<sup>4</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Please refer to correspondence dated, (b) (4), which addresses the proposed proprietary name, (b) (4). This name was found conditionally acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to all of the application deficiencies that have been identified in this letter.

### **SAFETY UPDATE**

When you respond to the above deficiencies, include a safety update as described at 21 CFR 601.2. The safety update should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level.

- (1) Describe in detail any significant changes or findings in the safety profile.
- (2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:
  - Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.
  - Present tabulations of the new safety data combined with the original application data.
  - Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described in the bullet above.
  - For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
- (3) Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified.
- (4) Provide case report forms and narrative summaries for each subject who died during a clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events.
- (5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data.
- (6) Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).

(7) Provide a summary of worldwide experience on the safety of this product. Include an updated estimate of use for product marketed in other countries.

(8) Provide English translations of current approved foreign labeling not previously submitted.

**ADDITIONAL COMMENTS**

We have the following comments/recommendations that are not approvability issues:

**PRODUCT QUALITY**

(b) (4)



(b) (4)



### **OTHER**

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 601.3(b). If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 601.3(c). You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "**RESUBMISSION**" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry *Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products*.

The product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, call

(b) (4)

Sincerely,

*{See appended electronic signature page}*

(b) (4)

Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

(b) (4)

03/22/2024 05:48:21 PM